1
00:00:00,000 --> 00:00:04,667
EloraTZP is Lilly's research name for combining eloralintide with tirzepatide.

2
00:00:04,667 --> 00:00:10,125
It describes a combination program rather than a new single peptide molecule.

3
00:00:10,125 --> 00:00:16,792
In September 2026, Lilly reported a forty-eight-week phase 2b study involving 367 adults with overweight

4
00:00:16,792 --> 00:00:20,292
or obesity and type 2 diabetes.

5
00:00:20,292 --> 00:00:27,375
The company reported larger numerical weight and A1C reductions with three of the four combinations than

6
00:00:27,375 --> 00:00:32,833
with tirzepatide alone. Gastrointestinal events occurred more frequently in the combination groups.

7
00:00:32,833 --> 00:00:37,083
These are sponsor-reported results that need full methodological scrutiny.

8
00:00:37,083 --> 00:00:43,333
They do not validate independently mixed products, and the tested population limits broader conclusions.